Drugs / 4H11-28z/fIL-12/EGFRt+
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02498912 | Aug 2015 → Aug 2026 overdue | cancer | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4H11-28z/fIL-12/EGFRt+ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02498912 ↗ |
| Modality | Cell therapy | “genetically-modified T cells” NCT02498912 ↗ |
| Route | Intravenous | “The IV infusion will be given first.” NCT02498912 ↗ |
| Target | MUC16 | “to target the MUC16ecto antigen” NCT02498912 ↗ |